The Effect of Uric Acid to High Density Lipoprotein Cholesterol Ratio on Prognosis in Diffuse Large B Cell Lymphoma

Year 2026, Volume: 12 Issue: 1, 13 - 21, 04.01.2026

Kadir Ilkkilic , Bayram Sen

https://doi.org/10.18621/eurj.1795016

Abstract

Objectives: International prognostic index (IPI) score, genetic mutation heterogeneity and inflammatory markers play an important role in predicting prognosis in diffuse large B-cell lymphoma (DLBCL). The uric acid to high-density lipoprotein cholesterol ratio (UHR) has been shown to be a new marker that allows better prediction of metabolic deterioration and inflammatory processes. The aim of the study is to evaluate the effect of UHR on prognosis in DLBCL patients.

Methods: In this retrospective cohort study, 120 patients were included. The effects of UHR on prognosis were evaluated.

Results: Of the total cohort, 79 patients survived, whereas 41 patients died. Mortality was higher in patients with higher UHR and IPI score ≥ 3 (P=0.047 and P=0.001, respectively). Univariate analysis revealed that age, Eastern Cooperative Oncology Group performance status (ECOG PS), disease stage, extranodal involvement, uric acid levels, IPI score, and UHR were significant predictors of mortality. Multivariate analysis revealed that ECOG PS, IPI score, and UHR were found to be independent predictors. Kaplan-Meier analysis showed that higher UHR (>0.1075) and IPI scores (≥3) were associated with decreased overall survival. (P=0.003 and P=0.005, respectively).

Conclusions: Elevated pre-treatment UHR independently predicts prognosis and is associated with reduced overall survival in patients with DLBCL. It may serve as a surrogate marker of systemic metabolic dysfunction and help identify high-risk patients alongside the IPI score.

Keywords

Diffuse Large B-Cell Lymphoma , Uric Acid to High Density Lipoprotein Cholesterol Ratio , Prognosis

Ethical Statement

This study was approved by the Recep Tayyip Erdoğan University Non-Interventional Clinical Research Ethics Committee (Decision No: 2025/201; date: 26.05.2025). All procedures were conducted in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments. As this is a retrospective study involving patient data obtained from medical records, the requirement for obtaining written informed consent was waived by the ethics committee.

References

• 1. Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679-690. doi: 10.1038/s41591-018-0016-8.
• 2. Ruppert AS, Dixon JG, Salles G, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020;135(23):2041-2048. doi: 10.1182/blood.2019002729.
• 3. Kunlayawutipong T, Rattanathammethee T, Punnachet T, et al. Prevalence and risk factors for hyperuricemia and hyperuricosuria in patients with hematologic malignancies. Front Med (Lausanne). 2024;11:1343000. doi: 10.3389/fmed.2024.1343000.
• 4. Prochazka KT, Melchardt T, Posch F, et al. NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients. Br J Cancer. 2016;115(10):1264-1272. doi: 10.1038/bjc.2016.325.
• 5. Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells. Oncogenesis. 2016;5(1):e189. doi: 10.1038/oncsis.2015.49.
• 6. Yvan-Charvet L, Pagler T, Gautier EL, et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science. 2010;328(5986):1689-1693. doi: 10.1126/science.1189731.
• 7. Pirro M, Ricciuti B, Rader DJ, Catapano AL, Sahebkar A, Banach M. High density lipoprotein cholesterol and cancer: Marker or causative? Prog Lipid Res. 2018;71:54-69. doi: 10.1016/j.plipres.2018.06.001.
• 8. Yu T, Luo D, Luo C, Xu-Monette ZY, Yu L. Prognostic and therapeutic value of serum lipids and a new IPI score system based on apolipoprotein A-I in diffuse large B-cell lymphoma. Am J Cancer Res. 2023;13(2):475-484.
• 9. Yiu A, Van Hemelrijck M, Garmo H, et al. Circulating uric acid levels and subsequent development of cancer in 493,281 individuals: findings from the AMORIS Study. Oncotarget. 2017;8(26):42332-42342. doi: 10.18632/oncotarget.16198.
• 10. Zhao D, Xu H, Tang F, Cui T, Sun X, Song G. Association of dynamic changes in metabolic syndrome components with clinical outcomes in diffuse large B-cell lymphoma. Front Oncol. 2025;15:1524498. doi: 10.3389/fonc.2025.1524498.
• 11. Bazmandegan G, Dehghani MH, Karimifard M, et al. Uric acid to HDL ratio: A marker for predicting incidence of metabolic syndrome in patients with type II diabetes. Nutr Metab Cardiovasc Dis. 2024;34(4):1014-1020. doi: 10.1016/j.numecd.2023.12.022.
• 12. Cheng Y, Zhang H, Zheng H, et al. Association between serum uric acid/HDL-cholesterol ratio and chronic kidney disease: a cross-sectional study based on a health check-up population. BMJ Open. 2022;12(12):e066243. doi: 10.1136/bmjopen-2022-066243.
• 13. Li Y, Jin-Si-Han EE, Feng C, et al. An evaluation model of hepatic steatosis based on CT value and serum uric acid/HDL cholesterol ratio can predict intrahepatic recurrence of colorectal cancer liver metastasis. Int J Clin Oncol. 2024;29(9):1263-1273. doi: 10.1007/s10147-024-02550-y.
• 14. Jaeger A, Gambheer SMM, Sun X, et al. Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms. Blood. 2023;141(23):2824-2840. doi: 10.1182/blood.2022015653.
• 15. Carbone A, Tripodo C, Carlo-Stella C, Santoro A, Gloghini A. The role of inflammation in lymphoma. Adv Exp Med Biol. 2014;816:315-333. doi: 10.1007/978-3-0348-0837-8_12.
• 16. Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837-842. doi: 10.1182/blood-2013-09-524108.
• 17. Catapano AL, Pirillo A, Bonacina F, Norata GD. HDL in innate and adaptive immunity. Cardiovasc Res. 2014;103(3):372-383. doi: 10.1093/cvr/cvu150.
• 18. Cockerill GW, Huehns TY, Weerasinghe A, et al. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation. 2001;103(1):108-112. doi: 10.1161/01.cir.103.1.108.
• 19. Cruz PM, Mo H, McConathy WJ, Sabnis N, Lacko AG. The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics. Front Pharmacol. 2013;4:119. doi: 10.3389/fphar.2013.00119.
• 20. Pedersen KM, Çolak Y, Bojesen SE, Nordestgaard BG. Low high-density lipoprotein and increased risk of several cancers: 2 population-based cohort studies including 116,728 individuals. J Hematol Oncol. 2020;13(1):129. doi: 10.1186/s13045-020-00963-6.
• 21. Gao R, Liang JH, Wang L, et al. Low serum cholesterol levels predict inferior prognosis and improve NCCN-IPI scoring in diffuse large B cell lymphoma. Int J Cancer. 2018;143(8):1884-1895. doi: 10.1002/ijc.31590.
• 22. Park B, Jung DH, Lee YJ. Predictive Value of Serum Uric Acid to HDL Cholesterol Ratio for Incident Ischemic Heart Disease in Non-Diabetic Koreans. Biomedicines. 2022;10(6):1422. doi: 10.3390/biomedicines10061422.
• 23. Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493-503. doi: 10.1016/S1470-2045(14)70263-3.
• 24. Bao C, Gu J, Huang X, You L, Zhou Z, Jin J. Cytokine profiles in patients with newly diagnosed diffuse large B-cell lymphoma: IL-6 and IL-10 levels are associated with adverse clinical features and poor outcomes. Cytokine. 2023;169:156289. doi: 10.1016/j.cyto.2023.156289.
• 25. Ndrepepa G. Uric acid and cardiovascular disease. Clin Chim Acta. 2018;484:150-163. doi: 10.1016/j.cca.2018.05.046.
• 26. Barter P, Gotto AM, LaRosa JC, et al; Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357(13):1301-10. doi: 10.1056/NEJMoa064278.
• 27. Li Z, Liu Q, Yao Z. The serum uric acid-to-high-density lipoprotein cholesterol ratio is a predictor for all-cause and cardiovascular disease mortality: a cross-sectional study. Front Endocrinol (Lausanne). 2024;15:1417485. doi: 10.3389/fendo.2024.1417485.